Cymabay Therapeutics (CBAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2018 | 09-2018 | 06-2018 | 03-2018 | 12-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -72,548 | -53,099 | -34,536 | -17,005 | -27,557 |
| Depreciation Amortization | -1,840 | -1,319 | -752 | -266 | -164 |
| Accounts receivable | 5,000 | 5,000 | 5,000 | 5,000 | -5,000 |
| Accounts payable and accrued liabilities | 662 | 318 | 25 | 727 | 412 |
| Other Working Capital | 8,859 | 10,113 | 7,242 | 4,288 | -3,041 |
| Other Operating Activity | 4,931 | 3,646 | 3,757 | 815 | 15,718 |
| Operating Cash Flow | $-54,936 | $-35,341 | $-19,264 | $-6,441 | $-19,632 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -53,582 | -80,822 | -92,443 | -89,609 | -67,501 |
| PPE Investments | -529 | -60 | -46 | -46 | -27 |
| Investing Cash Flow | $-54,111 | $-80,882 | $-92,489 | $-89,655 | $-67,528 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | -829 | N/A |
| Debt Repayment | -6,653 | -6,653 | -6,653 | N/A | -3,137 |
| Common Stock Issued | 141,641 | 141,617 | 140,078 | 139,452 | 102,856 |
| Financing Cash Flow | $134,988 | $134,964 | $133,425 | $138,623 | $99,719 |
| Beginning Cash Position | 23,054 | 23,054 | 23,054 | 23,054 | 10,495 |
| End Cash Position | 48,995 | 41,795 | 44,726 | 65,581 | 23,054 |
| Net Cash Flow | $25,941 | $18,741 | $21,672 | $42,527 | $12,559 |
| Free Cash Flow | |||||
| Operating Cash Flow | -54,936 | -35,341 | -19,264 | -6,441 | -19,632 |
| Capital Expenditure | -529 | -60 | -46 | -46 | -27 |
| Free Cash Flow | -55,465 | -35,401 | -19,310 | -6,487 | -19,659 |